Vaccines, vaccination, and vaccinology

Journal of Infectious Diseases

Volumn 187, Issue 9, 2003, Pages 1349-1359

  Plotkin, Stanley A ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Aventis Pasteur   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX VACCINE; GLYCOPROTEIN GP 120; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B VACCINE; HERPES SIMPLEX VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INFLUENZA VACCINE; LYME DISEASE VACCINE; MEASLES VACCINE; ORAL POLIOMYELITIS VACCINE; RABIES VACCINE; ROTAVIRUS VACCINE; RUBELLA VACCINE; TETANUS TOXIN; VACCINE;

BACTERIAL INFECTION; CLOSTRIDIUM TETANI; GENETIC ENGINEERING AND GENE TECHNOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNIZATION; INFLUENZA; INFLUENZA VIRUS; LYME DISEASE; MEASLES; POLIOMYELITIS; PRIORITY JOURNAL; REVIEW; ROTAVIRUS; RUBELLA; VACCINATION; VACCINIA VIRUS; VIRUS GENOME; VIRUS INFECTION;

ANIMALS; GENETIC ENGINEERING; HUMANS; LYME DISEASE; VACCINATION; VACCINES; VIRUS DISEASES; VIRUSES;

EID: 0037880383     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/374419     Document Type: Review

References (98)

1. Pasteur L. Communication faite à l'Académie des sciences, séance du 26 avril 1880 et à l'Académie de médecine, séance du 27 avril 1880. Oeuvres de Pasteur [VI] 1880:303.
2. Bland J, Clements J. Protecting the world's children: the story of WHO's immunization programme. World Health Forum 1998; 19:162-73.
3. Bendelac A, Medzhitov R. Adjuvants of immunity: harnessing innate immunity to promote adaptive immunity. J Exp Med 2002; 195:F19-23.
4. Plotkin SL, Plotkin SA. The history of vaccination. In: Plotkin SA, Orenstein WO, eds. Vaccines. 3rd ed. Philadelphia: WB Saunders, 1999:1-12.
5. BenMohamed L, Wechsler SL, Nesburn AB. Lipopeptide vaccines: yesterday, today, and tomorrow. Lancet Infect Dis 2002; 2:425-31.
6. Meloen RH, Langeveld JP, Schaaper WM, Slootstra JW. Synthetic peptide vaccines: unexpected fulfillment of discarded hope? Biologicals 2001; 29:233-6.
7. Murphy TV, Gargiullo PM, Massoudi MS, et al. Intussusception among infants given an oral rotavirus vaccine. N Engl J Med 2001; 344:564-72.
8. Clark HF, Furukawa T, Bell LM, Offit PA, Perrella PA, Plotkin SA. Immune response of infants and children to low-passage bovine rotavirus (strain WC3). Am J Dis Child 1986; 140:350-6.
9. Bernstein DI, Smith VE, Sherwood JR, et al. Safety and immunogenicity of live, attenuated human rotavirus vaccine 89-12. Vaccine 1998; 16:381-7.
10. Clark HF, Offit P, Ward RL. Safety, immunogenicity, and efficacy of a quadrivalent reassortant rotavirus vaccine (ARV) [abstract]. Pediatr Res 2002; 51:282.
11. Bernstein DI, Sack DA, Rothstein E, et al. Efficacy of live, attenuated, human rotavirus vaccine 89-12 in infants: a randomised placebo-controlled trial. Lancet 1999; 354:287-90.
12. Centers for Disease Control and Prevention. Progress towards the global eradication of poliomyelitis, 2001. Wkly Epidemiol Rec 2002; 77:98-107.
13. Martin J, Minor PD. Characterization of CHAT and Cox type 1 live-attenuated poliovirus vaccine strains. J Virol 2002; 76:5339-49.
14. Fogel A, Plotkin SA. Genetic changes in attenuated poliovirus strains cultivated on human intestine in vitro. Am J Epidemiol 1968; 87:385-95.
15. Kew O, Morris-Glasgow V, Landaverde M, et al. Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science 2002; 296:356-9.
16. Kew OM, Sutter RW, Nottay BK, et al. Prolonged replication of a type 1 vaccine-derived poliovirus in an immunodeficient patient. J Clin Microbiol 1998; 36:2893-9.
17. Cherkasova EA, Korotkova EA, Yakovenko ML, et al. Long-term circulation of vaccine-derived poliovirus that causes paralytic disease. J Virol 2002; 76:6791-9.
18. Cello J, Paul AV, Wimmer E. Chemical synthesis of poliovirus cDNA: generation of infectious virus in the absence of natural template. Science 2002; 297:1016-8.
19. Centers for Disease Control and Prevention. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1999; 48:1-28.
20. Smith G, Wileyto EP, Hopkins RB, Cherry BR, Maher JP. Risk factors for lyme disease in Chester County, Pennsylvania. Public Health Rep 2001; 116(Suppl 1):146-56.
21. Poland GA. Prevention of Lyme disease: a review of the evidence. Mayo Clin Proc 2001; 76:713-24.
22. Mettens P, Monteyne P. Life-style vaccines. Br Med Bull 2002; 62:175-86.
23. Sabin AB. My last will and testament on rapid elimination and ultimate global eradication of poliomyelitis and measles. Pediatrics 1992; 90:162-9.
24. Puschak R, Young M, McKee TV, Plotkin SA. Intranasal vaccination with RA 27-3 attenuated rubella virus. J Pediatr 1971; 79:55-60.
25. Sepulveda-Amor J, Valdespino-Gomez JL, Garcia-Garcia ML, et al. A randomized trial demonstrating successful boosting responses following simultaneous aerosols of measles and rubella (MR) vaccines in school age children. Vaccine 2002; 20:2790-5.
26. Dilraj A, Cutts FT, de Castro JF, et al. Response to different measles vaccine strains given by aerosol and subcutaneous routes to school-children: a randomised trial. Lancet 2000; 355:798-803.
27. Fernandez-De Castro J, Kumate-Rodriguez J, Sepulveda J, Ramirez-Isunza JM, Valdespino-Gomez JL. Measles vaccination by the aerosol method in Mexico [in Spanish]. Salud Publica Mex 1997; 39:53-60.
28. Granoff DM. Assessing efficacy of Haemophilus influenzae type b combination vaccines. Clin Infect Dis 2001; 33(Suppl 4):S278-87.
29. Goldblatt D, Richmond P, Millard E, Thornton C, Miller E. The induction of immunologic memory after vaccination with Haemophilus influenzae type b conjugate and acellular pertussis-containing diphtheria, tetanus, and pertussis vaccine combination. J Infect Dis 1999; 180:538-41.
30. Plotkin SA. Vaccination against the major infectious diseases. C R Acad Sci III 1999; 322:943-51.
31. Vassilev VB, Gil LH, Donis RO. Microparticle-mediated RNA immunization against bovine viral diarrhea virus. Vaccine 2001; 19:2012-9.
32. Halstead SB, Deen J. The future of dengue vaccines. Lancet 2002; 360:1243-5.
33. Monath TP, McCarthy K, Bedford P, et al. Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections. Vaccine 2002; 20:1004-18.
34. Guirakhoo F, Pugachev K, Arroyo J, et al. Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever - dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates. Virology 2002; 298:146-59.
35. Monath TP. Prospects for development of a vaccine against the West Nile virus. Ann NY Acad Sci 2001; 951:1-12.
36. Skiadopoulos MH, Surman SR, Riggs JM, Orvell C, Collins PL, Murphy BR. Evaluation of the replication and immunogenicity of recombinant human parainfluenza virus type 3 vectors expressing up to three foreign glycoproteins. Virology 2002; 297:136-52.
37. Schiller JT. Papillomavirus-like particle vaccines for cervical cancer. Mol Med Today 1999; 5:209-15.
38. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002; 347:1645-51.
39. Bojang KA, Milligan PJ, Pinder M, et al. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet 2001; 358:1927-34.
40. Watanabe T, Watanabe S, Neumann G, Kida H, Kawaoka Y. Immunogenicity and protective efficacy of replication-incompetent influenza virus-like particles. J Virol 2002; 76:767-73.
41. Liljestrom P, Garoff H. A new generation of animal cell expression vectors based on the Semliki Forest virus replicon. Biotechnology (NY) 1991; 9:1356-61.
42. Rayner JO, Dryga SA, Kamrud KI. Alphavirus vectors and vaccination. Rev Med Virol 2002; 12:279-96.
43. Robinson HL. Nucleic acid vaccines: an overview. Vaccine 1997; 15:785-7.
44. Reyes-Sandoval A, Ertl HC. DNA vaccines. Curr Mol Med 2001; 1:217-43.
45. Bot A, Shearer M, Bot S, et al. Induction of immunological memory in baboons primed with DNA vaccine as neonates. Vaccine 2001; 19:1960-7.
46. Donnelly JJ, Friedman A, Martinez D, et al. Preclinical efficacy of a prototype DNA vaccine: enhanced protection against antigenic drift in influenza virus. Nat Med 1995; 1:583-7.
47. Reddy ST, Ertl HC. The potential use of DNA vaccines for neonatal immunization. Curr Opin Mol Ther 1999; 1:22-9.
48. Prince AM, Whalen R, Brotman B. Successful nucleic acid based immunization of newborn chimpanzees against hepatitis B virus. Vaccine 1997; 15:916-9.
49. Scheerlinck JP, Casey G, McWaters P, et al. The immune response to a DNA vaccine can be modulated by co-delivery of cytokine genes using a DNA prime-protein boost strategy. Vaccine 2001; 19:4053-60.
50. Epstein SL, Tumpey TM, Misplon JA, et al. DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice. Emerg Infect Dis 2002; 8:796-801.
51. Tacket CO, Roy MJ, Widera G, Swain WF, Broome S, Edelman R. Phase 1 safety and immune response studies of a DNA vaccine encoding hepatitis B surface antigen delivered by a gene delivery device. Vaccine 1999; 17:2826-9.
52. O'Hagan DT. Recent developments in vaccine delivery systems. Curr Drug Targets Infect Disord 2001; 1:273-86.
53. Liu WJ, Zhao KN, Gao FG, Leggatt GR, Fernando GJ, Frazer IH. Polynucleotide viral vaccines: codon optimisation and ubiquitin conjugation enhances prophylactic and therapeutic efficacy. Vaccine 2001; 20:862-9.
54. Murphy BR, Collins PL. Live-attenuated virus vaccines for respiratory syncytial and parainfluenza viruses: applications of reverse genetics. J Clin Invest 2002; 110:21-7.
55. Neumann G, Watanabe T, Ito H, et al. Generation of infuenza A viruses entirely from cloned cDNAs. Proc Natl Acad Sci USA 1999; 96:9345-50.
56. Fodor E, Devenish L, Engelhardt OG, Palese P, Brownlee GG, Garcia-Sastre A. Rescue of influenza A virus from recombinant DNA. J Virol 1999; 73:9679-82.
57. Palese P, Garcia-Sastre A. Influenza vaccines: present and future. J Clin Invest 2002; 110:9-13.
58. Hilleman MR. Recombinant vector vaccines in vaccinology. Dev Biol Stand 1994; 82:3-20.
59. + T cells and antiviral protective immunity. J Virol 2001; 75:9665-70.
60. Sizemore DR, Branstrom AA, Sadoff JC. Attenuated Shigella as a DNA delivery vehicle for DNA-mediated immunization. Science 1995; 270:299-302.
61. Gonczol E, Plotkin S. Development of a cytomegalovirus vaccine: lessons from recent clinical trials. Expert Opin Biol Ther 2001; 1:401-12.
62. Berencsi K, Gyulai Z, Gonczol E, et al. A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-sero-negative subjects. J Infect Dis 2001; 183:1171-9.
63. Plotkin SA. Is there a formula for an effective CMV vaccine? J Clin Virol 2002; 25(Suppl 2):S13-21.
64. Pass RF, Duliege AM, Boppana S, et al. A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant. J Infect Dis 1999; 180:970-5.
65. Institute of Medicine. Vaccines for the 20th century: a tool for decision making. Washington, DC: National Academy of Science, 2002:1-460.
66. Excler JL, Plotkin SA. The prime-boost concept applied to HIV preventive vaccines. AIDS 1997; 11:S127-37.
67. Pialoux G, Excler JL, Riviere Y, et al. A primeboost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). AGIS Group, and l'Agence Nationale de Recherche sur le SIDA. AIDS Res Hum Retroviruses 1995; 11:373-81.
68. Amara RR, Villinger F, Altman JD, et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Vaccine 2002; 20:1949-55.
69. Shiver JW, Fu TM, Chen L, et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 2002; 415:331-5.
70. Moorthy V, Hill AV. Malaria vaccines. Br Med Bull 2002; 62:59-72.
71. Farina SF, Gao GP, Xiang ZQ, et al. Replication-defective vector based on a chimpanzee adenovirus. J Virol 2001; 75:11603-13.
72. Xiang Z, Gao G, Reyes-Sandoval A, et al. Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product. J Virol 2002; 76:2667-75.
73. Dhiman N, Bonilla R, O'Kane DJ, Poland GA. Gene expression microarrays: a 21st century tool for directed vaccine design. Vaccine 2001; 20:22-30.
74. De Groot AS, Sbai H, Aubin CS, McMurry J, Martin W. Immuno-informatics: mining genomes for vaccine components. Immunol Cell Biol 2002; 80:255-69.
75. Sette A, Livingston B, McKinney D, et al. The development of multi-epitope vaccines: epitope identification, vaccine design and clinical evaluation. Biologicals 2001; 29:271-6.
76. Jungblut PR, Zimny-Arndt U, Zeindl-Eberhart E, et al. Proteomics in human disease: cancer, heart and infectious diseases. Electrophoresis 1999; 20:2100-10.
77. Grandi G. Antibacterial vaccine design using genomics and proteomics. Trends Biotechnol 2001; 19:181-8.
78. Uehling DT, Hopkins WJ, Beierle LM, Kryger JV, Heisey DM. Vaginal mucosal immunization for recurrent urinary tract infection: extended phase II clinical trial. J Infect Dis 2001; 183(Suppl 1):S81-3.
79. Langermann S, Ballou WR Jr. Vaccination utilizing the FimCH complex as a strategy to prevent Escherichia coli urinary tract infections. J Infect Dis 2001; 183(Suppl 1):S84-6.
80. Cohen IR. T-cell vaccination for autoimmune disease: a panorama. Vaccine 2001; 20:706-10.
81. Klinman DM, Verthelyi D, Takeshita F, Ishii KJ. Immune recognition of foreign DNA: a cure for bioterrorism? Immunity 1999; 11:123-9.
82. Moingeon P, de Taisne C, Almond J. Delivery technologies for human vaccines. Br Med Bull 2002; 62:29-44.
83. Nakase H, Okazaki K, Tabata Y, et al. Rectal immunization with antigen-containing microspheres induces stronger Th2 responses than oral immunization: a new method for vaccination. Vaccine 2001; 20:377-84.
84. Chen D, Weis KF, Chu Q, et al. Epidermal powder immunization induces both cytotoxic T-lymphocyte and antibody responses to protein antigens of influenza and hepatitis B viruses. J Virol 2001; 75:11630-40.
85. Shi Z, Zeng M, Yang G, et al. Protection against tetanus by needle-free inoculation of adenovirus-vectored nasal and epicutaneous vaccines. J Virol 2001; 75:11474-82.
86. Huang Z, Dry I, Webster D, Strugnell R, Wesselingh S. Plant-derived measles virus hemagglutinin protein induces neutralizing antibodies in mice. Vaccine 2001; 19:2163-71.
87. Kapusta J, Modelska A, Figlerowicz M, et al. A plant-derived edible vaccine against hepatitis B virus. FASEB J 1999; 13:1796-9.
88. Kapusta J, Modelska A, Pniewski T, et al. Oral immunization of human with transgenic lettuce expressing hepatitis B surface antigen. Adv Exp Med Biol 2001; 495:299-303.
89. Yusibov V, Hooper D, Spitsin S, et al. Expression in plants and immunogenicity of plant virus-based experimental rabies vaccine. Vaccine 2002; 20:3155-64.
90. Cherry JD. Epidemiological, clinical, and laboratory aspects of pertussis in adults. Clin Infect Dis 1999; 28(Suppl 2):S112-7.
91. Frenkel D, Solomon B. Towards Alzheimer's beta-amyloid vaccination. Biologicals 2001; 29:243-7.
92. Chang MH, Chen CJ, Lai MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997; 336:1855-9.
93. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002; 347:1645-51.
94. Singh M, Das SK, Suri S, Singh O, Talwar GP. Regain of fertility and normality of progeny born during below protective threshold antibody titers in women immunized with the HSD-hCG vaccine. Am J Reprod Immunol 1998; 39:395-8.
95. Kantak KM, Collins SL, Lipman EG, Bond J, Giovanoni K, Fox BS. Evaluation of anti-cocaine antibodies and a cocaine vaccine in a rat self-administration model. Psychopharmacology (Berl) 2000; 148:251-62.
96. Munoz FM, Englund JA, Cheesman CC, et al. Maternal immunization with pneumococcal polysaccharide vaccine in the third trimester of gestation. Vaccine 2001; 20:826-37.
97. Vandepapeliere P. Therapeutic vaccination against chronic viral infections. Lancet Infect Dis 2002; 2:353-67.
98. Peters BS. The basis for HIV immunotherapeutic vaccines. Vaccine 2001; 20:688-705.